Cargando…

老年肺癌患者的免疫治疗疗效分析

BACKGROUND AND OBJECTIVE: Immunotherapy represented by immune checkpoint inhibitors (ICIs) has become the standard treatment for patients with non-oncogenic advanced non-small cell lung cancer (NSCLC). While lung cancer is most prevalent in elderly patients, these patients are rarely included in piv...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244504/
https://www.ncbi.nlm.nih.gov/pubmed/35747919
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.16
_version_ 1784738535273660416
collection PubMed
description BACKGROUND AND OBJECTIVE: Immunotherapy represented by immune checkpoint inhibitors (ICIs) has become the standard treatment for patients with non-oncogenic advanced non-small cell lung cancer (NSCLC). While lung cancer is most prevalent in elderly patients, these patients are rarely included in pivotal clinical trial studies. We aimed to describe the efficacy and safety of immunotherapy for elderly patients in the "real-world". METHODS: The data of older NSCLC patients and younger patients who received immunotherapy between July 2018 to October 2021 were retrospectively analyzed and the objective response rate (ORR) and progression-free survival (PFS) in different age groups (less than 60 years old was defined as the young group, 60 years-74 years old was the young old group, 75 years old and above was the old old group) were compared. And the impact of different clinical characteristics on treatment response and prognosis were analyzed in each age subgroup. RESULTS: A total of 21 young patients, 70 young old patients and 15 old old patients were included in this study, with ORR of 33.3%, 52.8% and 53.3%, respectively, without statistically significant difference (P=0.284). The median PFS was 9.1 mon, 7.6 mon and 10.9 mon, respectively, without statistically significant difference (P=0.654). Further analysis of the predictors of immunotherapy in each subgroup revealed that patients in the young old group and young group who received immunotherapy in the first line had a longer PFS. The difference of the incidence of adverse events was not statistically significant among the three groups (P>0.05). CONCLUSION: The efficacy and safety of immunotherapy in elderly patients were similar to those in younger patients, and PFS was superior in the first-line immunotherapy. Further prospective studies are still needed to explore predictors of immunotherapy in elderly NSCLC patients.
format Online
Article
Text
id pubmed-9244504
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-92445042022-07-14 老年肺癌患者的免疫治疗疗效分析 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Immunotherapy represented by immune checkpoint inhibitors (ICIs) has become the standard treatment for patients with non-oncogenic advanced non-small cell lung cancer (NSCLC). While lung cancer is most prevalent in elderly patients, these patients are rarely included in pivotal clinical trial studies. We aimed to describe the efficacy and safety of immunotherapy for elderly patients in the "real-world". METHODS: The data of older NSCLC patients and younger patients who received immunotherapy between July 2018 to October 2021 were retrospectively analyzed and the objective response rate (ORR) and progression-free survival (PFS) in different age groups (less than 60 years old was defined as the young group, 60 years-74 years old was the young old group, 75 years old and above was the old old group) were compared. And the impact of different clinical characteristics on treatment response and prognosis were analyzed in each age subgroup. RESULTS: A total of 21 young patients, 70 young old patients and 15 old old patients were included in this study, with ORR of 33.3%, 52.8% and 53.3%, respectively, without statistically significant difference (P=0.284). The median PFS was 9.1 mon, 7.6 mon and 10.9 mon, respectively, without statistically significant difference (P=0.654). Further analysis of the predictors of immunotherapy in each subgroup revealed that patients in the young old group and young group who received immunotherapy in the first line had a longer PFS. The difference of the incidence of adverse events was not statistically significant among the three groups (P>0.05). CONCLUSION: The efficacy and safety of immunotherapy in elderly patients were similar to those in younger patients, and PFS was superior in the first-line immunotherapy. Further prospective studies are still needed to explore predictors of immunotherapy in elderly NSCLC patients. 中国肺癌杂志编辑部 2022-06-20 /pmc/articles/PMC9244504/ /pubmed/35747919 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.16 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 临床研究
老年肺癌患者的免疫治疗疗效分析
title 老年肺癌患者的免疫治疗疗效分析
title_full 老年肺癌患者的免疫治疗疗效分析
title_fullStr 老年肺癌患者的免疫治疗疗效分析
title_full_unstemmed 老年肺癌患者的免疫治疗疗效分析
title_short 老年肺癌患者的免疫治疗疗效分析
title_sort 老年肺癌患者的免疫治疗疗效分析
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244504/
https://www.ncbi.nlm.nih.gov/pubmed/35747919
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.16
work_keys_str_mv AT lǎoniánfèiáihuànzhědemiǎnyìzhìliáoliáoxiàofēnxī
AT lǎoniánfèiáihuànzhědemiǎnyìzhìliáoliáoxiàofēnxī
AT lǎoniánfèiáihuànzhědemiǎnyìzhìliáoliáoxiàofēnxī
AT lǎoniánfèiáihuànzhědemiǎnyìzhìliáoliáoxiàofēnxī
AT lǎoniánfèiáihuànzhědemiǎnyìzhìliáoliáoxiàofēnxī
AT lǎoniánfèiáihuànzhědemiǎnyìzhìliáoliáoxiàofēnxī
AT lǎoniánfèiáihuànzhědemiǎnyìzhìliáoliáoxiàofēnxī
AT lǎoniánfèiáihuànzhědemiǎnyìzhìliáoliáoxiàofēnxī
AT lǎoniánfèiáihuànzhědemiǎnyìzhìliáoliáoxiàofēnxī